Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer
Andrew J. Armstrong, Susan Halabi, Patrick Healy, Joshi J. Alumkal, Carolyn Winters, Julie Kephart, Rhonda L. Bitting, Carey Hobbs, Colleen F. Soleau, Tomasz M. Beer, Rachel Slottke, Kelly Mundy, Evan Y. Yu, Daniel J. George
Dive into the research topics of 'Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer'. Together they form a unique fingerprint.